| Schedules of maximum clinical, regulatory or sales-based milestones and obligations pertaining to the significant license agreements that have been paid, expensed or accrued |
The below table represents the maximum clinical, regulatory or sales-based milestones as reflected within the significant license agreements, certain of which have been paid in prior periods or are accrued as presented in the table below (in thousands): | | | | | | | | | | | | Maximum | | Maximum | | Maximum | | | Clinical | | Regulatory | | Sales-based | Agreements | | Milestones | | Milestones | | Milestones | MSK | | | $ 2,450 | | | $ 9,000 | | | $ 20,000 | CD33 | | | 550 | | | 500 | | | 7,500 | MabVax | | | 200 | | | 1,200 | | | — | SADA | | | 4,730 | | | 18,125 | | | 23,750 |
The below table represents all obligations pertaining to the significant license agreements that have been paid, expensed, or accrued for during the three and six months ended June 30, 2024 and 2023, and as of June 30, 2024 and December 31, 2023 (in thousands) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Cash paid | | Cash paid | | Expense | | Expense | | Expense | | Expense | | Accrued | | Accrued | | Accrued | | Accrued | | | | six | | six | | three | | six | | three | | six | | liabilities | | liabilities | | liabilities | | liabilities | | | | months | | months | | months | | months | | months | | months | | current | | non-current | | current | | non-current | | | | ended | | ended | | ended | | ended | | ended | | ended | | as of | | as of | | as of | | as of | | | | June 30, | | June 30, | | June 30, | | June 30, | | June 30, | | June 30, | | June 30, | | June 30, | | December 31, | | December 31, | | Agreements | | 2024 | | 2023 | | 2024 | | 2024 | | 2023 | | 2023 | | 2024 | | 2024 | | 2023 | | 2023 | | MSK | | $ | 2,377 | | $ | 3,245 | | $ | 1,503 | | $ | 2,887 | | $ | 1,479 | | $ | 2,702 | | $ | 2,962 | | $ | 1,950 | | $ | 2,452 | | $ | 1,950 | | CD33 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | 300 | | | — | | | 300 | | MabVax | | | — | | | — | | | 10 | | | 10 | | | — | | | — | | | 10 | | | — | | | — | | | — | | SADA | | | 875 | | | 605 | | | — | | | — | | | — | | | — | | | 1,550 | | | 1,700 | | | 1,000 | | | 3,125 | |
|
| Maturities of operating lease liabilities |
Maturities of operating lease liabilities as of June 30, 2024 and December 31, 2023 were as follows (in thousands): | | | | | | | | | | | | | June 30, 2024 | | December 31, 2023 | Remainder of 2024 | | $ | 491 | | $ | — | Years ending December 31, | | | | | | | 2024 | | | — | | | 996 | 2025 | | | 681 | | | 526 | 2026 | | | 187 | | | — | 2027 | | | 16 | | | — | Total lease payments | | | 1,375 | | | 1,522 | Less: Imputed interest | | | (101) | | | (103) | Total operating lease liabilities as of period end | | $ | 1,274 | | $ | 1,419 |
|